 Clinical Oncology News | Everolimus Indication Expanded Clinical Oncology News Everolimus Indication Expanded. The FDA has approved everolimus (Afinitor, Novartis) for advanced hormone receptorāpositive, HER2-negative breast cancer in combination with exemestane after recurrence or progression following letrozole or anastrozole. |
